BioScience Trends
Reviews
Research progress on the direct antiviral drugs for hepatitis C virus
Jianjun GaoChuanxia Ju
Author information
JOURNALS FREE ACCESS

Volume 11 (2017) Issue 1 Pages 41-45

Details
Download PDF (308K) Contact us
Abstract

Hepatitis C, caused by the hepatitis C virus (HCV) that attacks the liver and leads to inflammation, is a severe threat to human health. Pegylated interferon α (INF-α) and ribavirin based therapy was once the standard therapy for HCV infection. However, it is suboptimal in efficacy and poorly tolerated in some patients. In the last five years, four classes of direct antiviral drugs (NAAs) that target non-structural proteins (NS) of the virus including NS3/NS4A, NS5A, and NS5B have been developed and opened a new era in HCV treatment as they are more effective and tolerable than the INF-α and ribavirin combination regimen. Importantly, the newly introduced multiple NAAs combination therapy makes it possible to eradicate all genotypes of HCV. We review recent progress on the research and development of DAAs in the present article.

Information related to the author
© 2017 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
Previous article Next article

Recently visited articles
feedback
Top